Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares)
85,436,464 (as at 15 Apr 2025)
Industry
Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date
15 Apr 2025
Financial Year Ends
-
Chairman
Zhu Zhongyuan
Principal Office
40/F
Dah Sing Financial Centre
248 Queen's Road East
Wanchai, Hong Kong
Place of Incorporation
Cayman Islands
Listing Category
Primary Listing
Primary Market
Depositary
DR Ratio
Description
Amount Outstanding
-
-
Subscription Rights per Unit
Subscription price/Strike price
Listing Date
The entitlement ratio in general represents the number of warrants required to be exercised into one share or one unit of the underlying asset (subject to any adjustments as may be necessary to reflect any capitalization, rights issue, distribution or the like).Entitlement Ratio
Subscription Period
Underlying Stock Code
Trading Currency